Kristina Oresic Bender

Title: Innovations by Kristina Oresic Bender

Introduction

Kristina Oresic Bender is an accomplished inventor based in Redwood City, CA (US). She has made significant contributions to the field of medical research, particularly in the treatment of infections caused by Clostridium difficile. Her innovative work has led to the development of a patent that addresses the toxicity associated with this infection.

Latest Patents

Kristina holds a patent for the "Use of small molecules for the treatment of clostridium difficile toxicity." This patent discloses methods and compositions aimed at reducing toxicity associated with infection by inhibiting toxin B (TcdB) and/or toxin A (TcdA). The compounds involved include ebselen compounds, such as ebselen and its salts, ebselen functional analogues, and ebselen structural analogues, along with certain amide derivatives. Notable formulas include Formula I, e.g., 1-methyl-3-phenylpropylamine; Formula II, e.g., 2,2'-diselane-1,2-diylbis[N-(2,4-difluorophenyl)benzamide]; and Formula III, e.g., 2-(2-methoxy-5-methylphenyl)-1,2-benzoselenazol-3-one. The compositions may be included in a colon-retentive formulation that enhances the residence and release of the compound in the area where the infection is active.

Career Highlights

Kristina is affiliated with Leland Stanford Junior University, where she continues her research and development efforts. Her work has garnered attention for its potential impact on public health, particularly in combating antibiotic-resistant infections.

Collaborations

Some of her notable coworkers include Aaron Puri and Aimee Shen, who contribute to her research initiatives and collaborative projects.

Conclusion

Kristina Oresic Bender's innovative contributions to medical research exemplify the importance of developing new treatments for challenging infections. Her patent reflects a significant advancement in the field, showcasing her dedication to improving health outcomes.